• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Mylan

Mylan

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  5. Research
  1. Mylan Launches First Generic Klor-Con® Extended-Release Tablets

    Mylan Launches First Generic Klor-Con® Extended-Release Tablets

  2. Mylan Launches Generic Precedex™ Injection - Another Key Product Approval

    Mylan Launches Generic Precedex™ Injection - Another Key Product Approval

  3. UPDATE: Apple sets intraday record; PetSmart considers sale

    UPDATE: Apple sets intraday record; PetSmart considers sale

  4. ADR Shares End Mixed; Luxottica Shares Active

    ADR Shares End Mixed; Luxottica Shares Active

  5. What Migration Can (and Can’t) Do for a Country’s GDP

    Mylan Laboratories MYL reported impressive second-quarter results Wednesday. However, most of the improvement was temporary and will not affect our fair value estimate. The quarter was only slightly better than we expected after excluding a one-time litigation payment and proceeds from a product ...

  6. UPDATE: Inversions are not such a sweet deal for fund investors

    UPDATE: Inversions are not such a sweet deal for fund investors

  7. Research and Markets: The Overview of Japanese Generic Drug Market

    Research and Markets: The Overview of Japanese Generic Drug Market

  8. ADR Shares End Lower; Statoil Shares Trade Actively

    ADR Shares End Lower; Statoil Shares Trade Actively

  9. UPDATE: Scrap corporate income tax, and make shareholders pay

    UPDATE: Scrap corporate income tax, and make shareholders pay

  10. UPDATE: Corporate tax is broken and needs major surgery

    UPDATE: Corporate tax is broken and needs major surgery

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.